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ABSTRACT
A new technique was used to simultaneously determine human cytomegalovirus (HCMV)-specific
CD4+ and CD8+ T-cells in highly active anti-retroviral therapy (HAART)-naive and HAART-treated
patients infected with human immunodeficiency virus (HIV). HIV-infected patients with HCMV
infection, but without HCMV disease, showed low numbers of HCMV-specific CD4+ cells and high
numbers of CD8+ T-cells, both before and during HAART. HIV-infected patients with HCMV disease
had no HCMV-specific CD4+ T-cells and extremely low levels of CD8+ T-cells. Resolution of disease
during HAART was associated with rescue of specific CD4+ T-cells and a large increase in the specific
CD8+ T-cell count. Thus, HAART does not completely restore the normal immune function. In HIV-
infected patients, sustained control of HCMV infection requires high frequencies of specific CD8+ T-
cells.
Keywords CD4+ ⁄CD8+ T-cells, cytomegalovirus, highly active anti-retroviral therapy (HAART), human immuno-
deficiency virus, immune function, protective immunity
Original Submission: 30 March 2006; Revised Submission: 12 May 2006; Accepted: 19 June 2006
Clin Microbiol Infect 2007; 13: 19–24
INTRODUCTION
Before the introduction of highly active anti-
retroviral therapy (HAART), human cytomegalo-
virus (HCMV) was the most common viral
opportunistic pathogen in patients infected with
human immunodeficiency virus (HIV). Following
the introduction of HAART, morbidity caused
by HCMV and other opportunistic pathogens
decreased dramatically [1]. HAART-induced
immune reconstitution allowed control of HCMV
infection in the absence of secondary anti-HCMV
prophylaxis [2]. However, multiple aspects of
protective immunity against HCMV and other
opportunistic pathogens in HAART-naive or
HAART-treated HIV-infected patients are not
understood fully. HCMV may contribute to a
delayed CD4+ T-cell response after initiation of
HAART [3]. In addition, HAART does not seem
to induce a complete reconstitution of the T-cell
compartment, even after years of viral suppres-
sion, since depletions or perturbations in both the
CD4+ and CD8+ T-cell repertoire are not restored
completely [4].
It is well-known that both CD4+ and CD8+ T-
cells are needed for long-term control of HCMV
infection [5]. In this context, the present study
used a recently developed technique [6], capable
of detecting HCMV-specific CD4+ and CD8+ T-
cells simultaneously, in an attempt to provide
additional information concerning HAART-
induced reconstitution of the memory T-cell
compartment.
PATIENTS AND METHODS
Two groups of HIV-infected HCMV-seropositive individuals
were analysed. The first group comprised 39 subjects (median
age 47 years, range 34–71 years) who had never experienced
HCMV disease, including 12 HAART-naive subjects (median
CD4+ T-cells 83 ⁄ lL blood, range 7–635 ⁄ lL blood), ten patients
who were examined after receiving HAART for 3 years
(median pre-HAART baseline CD4+ T-cells 62 ⁄ lL blood, range
2–635 ⁄lL blood), and 17 patients who were examined after
receiving HAART for 7 years (median baseline CD4+ T-cells
120 ⁄lL blood, range 2–604 ⁄ lL blood). The second group
comprised 17 patients (median age 44 years, range
33–69 years) with active or previous HCMV disease, including
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three HAART-naive patients (CD4+ T-cells 18, 26 and 79 ⁄lL
blood, respectively) with active HCMV disease (two retinitis
and one systemic infection), nine patients with previous
HCMV disease (seven retinitis and two systemic infections)
who were examined after receiving HAART for 3 years
(median baseline CD4+ T-cells 33 ⁄ lL blood, range 9–70 ⁄lL
blood), and five patients with previous HCMV retinitis who
were examined after receiving HAART for 7 years (median
baseline CD4+ T-cells 84 ⁄ lL blood, range 55–93 ⁄lL blood).
Patients were tested for total and for HCMV-specific CD4+ and
CD8+ T-cells, and for HCMV DNA in blood. A long-term
follow-up of HCMV-specific T-cell quantification was conduct-
ed in four patients (two with and two without HCMV disease).
Forty age-matched HCMV-seropositive and 11 HCMV-sero-
negative healthy subjects who were HIV-seronegative were
tested as controls.
HCMV-specific CD4+ and CD8+ T-cells were quantified
simultaneously by a novel method using autologous, mono-
cyte-derived, HCMV-infected immature dendritic cells (DCs),
as described previously [6]. In brief, following in-vitro gen-
eration from peripheral blood mononuclear cells, DCs were
infected for 24 h with an endotheliotropic and leukotropic
HCMV strain (VR1814). HCMV-infected DCs were then
co-cultured overnight with autologous thawed peripheral
blood mononuclear cells at a ratio of 1:20 in the presence of
brefeldin A 10 lg ⁄mL (Sigma, St Louis, MO, USA) to prevent
cytokine release. Finally, peripheral blood mononuclear cells
were tested for the frequency of HCMV-specific CD4+ and
CD8+ interferon (IFN)-c-producing T-cells by flow cytometry
(FACSCalibur; Becton-Dickinson, San Jose, CA, USA).
Absolute CD3+CD4+ and CD3+CD8+ T-cell counts were
determined for peripheral blood samples (Epics-XL flow
cytometer; Beckman Coulter, Fullerton, CA, USA). Total
numbers of HCMV-specific CD4+ and CD8+ T-cells were
calculated by multiplying the percentages of HCMV-specific
T-cells positive for IFN-c by the relevant absolute CD4+ and
CD8+ T-cell counts. Patients with <0.2 HCMV-specific
T-cells ⁄lL blood were designated as non-responders (i.e.,
patients without virus-specific immunity), patients with >0.4
HCMV-specific T-cells ⁄ lL blood were designated as respond-
ers, and patients with 0.2–0.4 HCMV-specific T-cells ⁄lL blood
were designated as low-responders [6].
The presence of HCMV DNA in blood was determined by a
real-time PCR method [7]. Differences between medians were
compared by the Mann–Whitney U-test, and correlations were
determined by Spearman’s correlation test.
RESULTS
Within the group of HIV-infected patients with no
experience of HCMV disease, HCMV-specific
CD4+ T-cells were detected in nine (75%) of 12
HAART-naive patients. In detail, HCMV-specific
CD4+ T-cells were detected in five of eight
patients with <100 total CD4+ T-cells ⁄lL, and in
all four patients with >100 total CD4+ T-cells ⁄ lL.
However, levels of HCMV-specific CD4+ T-cells
were significantly lower than those found in
healthy controls (median 0.750 cells ⁄ lL, range
0.000–8.890 cells ⁄ lL vs. median 3.550 cells ⁄lL,
range 0.660–24.910 cells ⁄lL). HCMV-specific
CD8+ T-cells were detected in all patients exam-
ined (even in the absence of specific CD4+ T-cells),
with a median count (27.830 cells ⁄lL, range
3.380–76.797 cells ⁄ lL) which was significantly
higher (p 0.001) than that found in controls
(median 2.545 cells ⁄ lL, range 0.400–25.590
cells ⁄lL). HCMV was detected in the blood of
five (42%) of these 12 patients, thus indicating a
sub-clinical reactivation (Fig. 1A).
HCMV-specific CD4+ T-cells were detected in
all patients examined who had no history of
HCMV disease after receiving HAART for
3 years, and in 15 (88%) of 17 patients who had
received long-term (>7 years) HAART, while
HCMV-specific CD8+ T-cells were detected in all
patients of both groups. Levels of HCMV-specific
CD4+ and CD8+ T-cells were not significantly
different in patients examined after receiving
HAART for 3 or 7 years when compared with
HAART-naive patients (Fig. 1A).
In the group of patients with HCMV disease,
the three HAART-naive AIDS patients with active
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Fig. 1. Absolute number (A) and percentage (B) of human
cytomegalovirus (HCMV)-specific CD4+ and CD8+ T-cells
in healthy HCMV-seropositive subjects and in the different
groups of patients infected with human immunodeficiency
virus. The horizontal dotted lines in (A) indicate the
equivocal zone. Below this zone, subjects are non-reactive
(negative); above it, subjects are reactive (positive).
HAART, highly active anti-retroviral therapy.
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disease completely lacked specific CD4+ T-cells
(all had <100 total CD4+ T-cells ⁄ lL), while speci-
fic CD8+ T-cells were present at very low levels
(0.493, 0.497 and 1.300 cells ⁄lL, respectively)
when compared with either HAART-naive
patients with no disease or healthy controls.
Patients with resolution of HCMV disease after
receiving HAART showed reconstitution of both
specific CD4+ and CD8+ T-cells. In fact, specific
CD4+ T-cells were detectable in eight (89%) of
nine and four (80%) of five patients examined
after receiving HAART for 3 and 7 years, respect-
ively, whereas CD8+ T-cells were present at high
levels in all patients. After these patients had
received HAART, levels of HCMV-specific T-cells
were in the range of those observed for patients
with no experience of HCMV disease (Fig. 1A).
No HAART-treated patient (both with and with-
out previous HCMV disease) had HCMV detect-
able in blood.
The high number of HCMV-specific CD8+
T-cells found in both HIV-seropositive patients
with resolution of previous HCMV disease and in
patients with no experience of HCMV disease was
not caused solely by the high level of total CD8+
T-cells found in these patients (data not shown).
In these patient populations, the percentage of
HCMV-specific T-cells among total CD8+ T-cells
(ranging from 0.16% to 33%) was significantly
(p <0.05) higher than in healthy controls (ranging
from 0.08% to 5.32%). In contrast, the three
patients with active HCMV disease showed very
low percentages of specific CD8+ T-cells (0.09–
0.11%). The percentage of HCMV-specific T-cells
among total CD4+ T-cells was in the range for
healthy controls, except for patients with active
HCMV disease lacking specific CD4+ T-cells
(Fig. 1B).
No significant correlation was found between
baseline pre-HAART CD4+ T-cell counts and
levels of HCMV-specific CD4+ and CD8+ T-cell
counts detected after receipt of HAART for either
3 or 7 years (both in patients with and without
HCMV disease) (data not shown). However, there
was a significant correlation between levels of
HCMV-specific CD4+ and CD8+ T-cells (p <0.01,
r 0.61) at each time point.
The results obtained following monitoring of
HCMV-specific T-cell immunity in four patients
are shown in Fig. 2. For patient A (who never
suffered from HCMV disease), no significant
variation in specific T-cell numbers was observed
during several years of HAART. For patient B
(showing only sub-clinical HCMV reactivation),
control of HCMV infection was achieved by
HCMV-specific CD8+ T-cells alone persisting in
blood in the absence of detectable specific CD4+
T-cells. Patients C and D suffered from HCMV
disease. In patient C, a disseminated HCMV
infection was controlled, following treatment with
ganciclovir, by an initial increase in HCMV-
specific CD8+ T-cells alone, followed by rescue
of specific CD4+ T-cells. Repeated retinitis epi-
sodes were observed in patient D, who initially
showed no specific CD4+ T-cells and low levels of
specific CD8+ T-cells, followed by an increase in
CD8+ T-cells and the appearance of CD4+ T-cells
that resulted in control of the infection.
DISCUSSION
Levels of HCMV-specific CD4+ and CD8+ T-cells
were determined in HIV-infected patients with
either active or controlled HCMV disease, and
also in patients with no experience of HCMV
disease. HAART-naive and medium-term
(3 years) or long-term (7 years) HAART-treated
patients were analysed using a novel approach.
Compared with methods exploiting stimuli given
by single peptides or peptide mixes, or based on
tetramer staining, the novel methodological ap-
proach [6] enabled a more comprehensive assess-
ment of the HCMV-specific T-cell reconstitution,
with the following advantages: (i) HLA restriction
does not limit the applicability of the assay; (ii)
different antigenic viral proteins are presented on
DC membranes besides pp65 and p72 (the two
targets used most widely for the study of HCMV-
specific CD8+ T-cells) [6,8]; and (iii) the same
stimulus is adopted for simultaneous quantifica-
tion of both HCMV-specific CD4+ and CD8+
T-cells, as well as for their functional evaluation.
The main finding of this study was that, in
HIV-infected patients, sustained control of
HCMV infection is achieved by high frequencies
of virus-specific CD8+ T-cells, which are main-
tained even after long-term HAART and in the
absence of detectable HCMV in blood. Although
other factors not investigated in this study (e.g.,
neutralising antibodies or natural killer cells) may
have contributed to control of HCMV infection,
the findings are in keeping with previous studies
reporting high levels of activated HCMV-specific
CD8+ T-cells and a low T-helper response in
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HIV-infected patients receiving HAART [9,10],
while low levels or an absence of IFN-c-produ-
cing HCMV-specific CD8+ T-cells have been
associated with the occurrence of HCMV
disease [11]. Previous studies have not reported
an association between the magnitude of the
CD8+ T-cell response and protection from
HCMV disease. Control of HCMV infection
was instead correlated with diversity of T-cell
repertoire and recovery of early differentiated
(CD27+ CD28+) T-cells, while terminally differ-
entiated effectors did not seem to confer pro-
tection [12,13]. However, those studies focused
only on pp65- and ⁄ or p72-specific CD8+ T-cells,
and this may have biased the quantification of
virus-specific T-cells. The methodological ap-
proach adopted in the present study may have
provided a more comprehensive assessment of
the magnitude of the anti-HCMV CD8+ T-cell
reconstitution.
101
102
103
104
105
106
ANR
 VIH
L
m/seip
oc
d
o
olb
A
101
102
103
104
105
106
Sub-clinical HCMV reactivation
ANR
 VIH
L
m/seip
oc
d
o
olb
B
0
0.4
12 24 36 48 60 72 84 96
1
10
100
1000
Months of HAART
cificeps
-V
MCH
 d
na
 lat
oT
/sllec
 T-
µ
d
o
olb
 L
0
0.4
0 3 6 9 12 15
1
10
100
1000
Months of HAART
cificeps
-V
MCH
 d
na
 lat
oT
/sllec
 T-
µ
d
o
olb
 L
101
102
103
104
105
106 GCV
HCMV systemic infectionC
ANR
 VIH
L
m/seip
oc
d
o
olb
101
102
103
104
105
106 GCV
HCMV
retinitis
PFA
ANR
 VIH
L
m/seip
oc
d
o
olb
D HCMV
retinitis
0
0.4
0 3 6 9 12 15
1
10
100
1000
Total CD4+ T-cells HCMV-spec. CD4+ T-cells
Months of HAART
cificeps
-V
MCH
 d
na
 lat
oT
/sllec
 T-
µ
d
o
olb
 L
0
0.4
0 3 6 9 12 15
1
10
100
1000
Total CD8+ T-cells HCMV-spec. CD8+ T-cells
Months of HAART
cificeps
-V
MCH
 d
na
 lat
oT
/sllec
 T-
µ
d
o
olb
 L
Fig. 2. Follow-up of total and human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T-cells in four patients infected
with human immunodeficiency virus (HIV). Arrows indicate the occurrence of HCMV disease or sub-clinical reactivation.
GCV, ganciclovir treatment; PFA, foscarnet treatment; HAART, highly active anti-retroviral therapy.
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Patients with active HCMV disease had no
specific CD4+ T-cells, as has been observed
previously [14,15], and very low levels of specific
CD8+ T-cells. These patients were able to control
HCMV infection only after an increase in virus-
specific CD8+ T-cells, while specific CD4+ T-cells
appeared later. Patients without HCMV disease
had relatively high levels (up to 33%) of HCMV-
specific CD8+ T-cells. These findings substantially
agree with recent reports in the literature [16,17].
The increase in HCMV-specific CD8+ T-cells
appears to be an adaptation of the host immune
system to a new CD4+ ⁄CD8+ balance in order to
control HCMV infection in the absence of a
normal T-helper activity [9,10]. However, patients
undergoing HAART did not show a normalisa-
tion of HCMV-specific CD8+ T-cell levels (when
compared with healthy subjects), even after
receiving anti-retroviral therapy for several years.
Although a correlation between levels of HCMV-
specific CD4+ and CD8+ T-cells was found, virus-
specific CD8+ T-cells were also observed in some
patients in the absence of detectable specific CD4+
T-cells, as reported previously [18].
It remains to be determined whether high
levels of HCMV-specific CD8+ T-cells are gen-
erated in response to repeated antigenic stimuli,
or whether, after an initial increase to control
HCMV reactivation (concomitantly with defect-
ive CD4+ T-cell activity), they are kept stable by
homeostatic signals in an antigen-independent
way. Even if HCMV was not detectable in the
blood of HAART-treated patients, it cannot be
excluded that virus replication below the level
of detection, or restricted to local body sites,
may have occurred. However, low levels of
HCMV-specific IFN-c-producing CD8+ T-cells
have been found in HIV-infected children with
persistent HCMV excretion [19]. Nevertheless, in
HIV-infected patients (as in healthy subjects),
HCMV-specific CD8+ T-cells are mainly inter-
leukin-7 receptora-negative [20], thus excluding
a possible role for at least interleukin-7 in the
maintenance of HCMV-specific CD8+ T-cells.
Moreover, only circulating lymphocytes were
addressed in the present study, and it cannot be
excluded that changes in homing properties
might be important in explaining the dis-
crepancies observed. Regardless of the mechan-
ism involved in the sustained increase in
HCMV-specific CD8+ T-cells, it appears to be
a hallmark of HIV infection that does not
correlate with the immunodeficiency stage
developed before initiation of HAART (i.e.,
pre-HAART total CD4+ T-cell depletion), and
should also be investigated with regard to other
pathogens.
The fact that high levels of HCMV-specific
CD8+ T-cells persist after several years of
HAART is, in itself, an additional indication
that anti-retroviral therapy does not lead to a
complete restoration of the immune function.
Accumulation of anti-HCMV CD8+ T-cells has
been reported to be a consequence of ageing,
leading to reduction of the T-cell pool available
to confront other antigens [21,22]. Whether this
is a marker of rapid immune senescence
induced by HIV infection [23], or simply repre-
sents a harmless homeostatic adaptation of the
T-cell compartment of chronic HIV carriers,
should be evaluated in further studies.
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